Dr Virginia Kaklamani speaks to ecancer about a subgroup analysis of patients from the Emerald Phase 3 study of elacestrant, which previously reported positive results meeting both its pre-specified primary endpoints. 

This analysis showed with a non-pre-specified subgroup of patients with ER+/HER2- metastatic breast cancer without prior chemotherapy in the metastatic setting that elacestrant significantly prolonged progression-free-survival (PFS) compared to standard of care endocrine therapy.

Dr Kaklamani then discusses the next steps for the study.

свернуть